Srirama S Venkataraman

Dr. Srirama S Venkataraman


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2022 in Cureus
Verified
Journal Article
Open access
PSPoorvi Satya
Poorvi Satya
JJJohn Adams Jr.
John Adams Jr.
SVSrirama S Venkataraman
Srirama S Venkataraman
DKDinesh Kumar
Dinesh Kumar
RNRam Narayanan
Ram Narayanan
JMJoseph Nicholas Macaluso
Joseph Nicholas Macaluso
This paper describes the workflow of transperineal prostate biopsy (TBx) using the single-sided, low-field Promaxo MRI system (Promaxo Inc., Oakland, California, United States) operating at a field strength ranging between 58 and 74 millitesla (mT). Prostate cancer (PCa) is the leading cause of cancer-related death and the second most frequently diagnosed cancer in men. Systematic biopsy (SBx) with 12-14 cores is the preferred standard of care procedure. The blinded approach of SBx, however, results in several shortcomings, including high rates of false negatives and increased infection rates due to the transrectal approach. The evolution of clinical use and scientific research using different prostate biopsy modalities is discussed, including the potential for the Promaxo MRI system to mitigate logistical constraints often associated with standard magnetic resonance (MR)-guided biopsy through the utilization of an office-based, low-field MRI.

9 January 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
DLDang Bich Thuy Le
Dang Bich Thuy Le
RNRam Narayanan
Ram Narayanan
MSMeredith Sadinski
Meredith Sadinski
ANAleksandar Nacev
Aleksandar Nacev
Yuling YanYuling Yan
Yuling Yan
SVSrirama S Venkataraman
Srirama S Venkataraman
This study evaluates the feasibility of using Haralick texture analysis on low-field, T2-weighted MRI images for detecting prostate cancer, extending current research from high-field MRI to the more accessible and cost-effective low-field MRI. A total of twenty-one patients with biopsy-proven prostate cancer (Gleason score 4+3 or higher) were included. Before transperineal biopsy guided by low-field (58–74mT) MRI, a radiologist annotated suspicious regions of interest (ROIs) on high-field (3T) MRI. Rigid image registration was performed to align corresponding regions on both high- and low-field images, ensuring an accurate propagation of annotations to the co-registered low-field images for texture feature calculations. For each cancerous ROI, a matching ROI of identical size was drawn in a non-suspicious region presumed to be normal tissue. Four Haralick texture features (Energy, Correlation, Contrast, and Homogeneity) were extracted and compared between cancerous and non-suspicious ROIs. Two extraction methods were used: the direct computation of texture measures within the ROIs and a sliding window technique generating texture maps across the prostate from which average values were derived. The results demonstrated statistically significant differences in texture features between cancerous and non-suspicious regions. Specifically, Energy and Homogeneity were elevated (p-values: <0.00001–0.004), while Contrast and Correlation were reduced (p-values: <0.00001–0.03) in cancerous ROIs. These findings suggest that Haralick texture features are both feasible and informative for differentiating abnormalities, offering promise in assisting prostate cancer detection on low-field MRI.